KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
KALA BIO (NASDAQ: KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 11:50 a.m. ET in Boston, MA.
The company's management team will deliver the presentation and will be available for one-on-one meetings throughout the day. Interested parties can access the webcast and subsequent recording through the 'Presentations' section on www.kalarx.com.
KALA BIO (NASDAQ: KALA), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie innovative per le malattie oculari, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione è programmata per 5 marzo 2025, alle 11:50 ET a Boston, MA.
Il team di gestione dell'azienda effettuerà la presentazione e sarà disponibile per incontri individuali durante tutta la giornata. Le parti interessate possono accedere al webcast e alla registrazione successiva attraverso la sezione 'Presentazioni' su www.kalarx.com.
KALA BIO (NASDAQ: KALA), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de terapias innovadoras para enfermedades oculares, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación está programada para 5 de marzo de 2025, a las 11:50 a.m. ET en Boston, MA.
El equipo de gestión de la compañía realizará la presentación y estará disponible para reuniones uno a uno durante todo el día. Las partes interesadas pueden acceder a la transmisión en vivo y a la grabación posterior a través de la sección 'Presentaciones' en www.kalarx.com.
KALA BIO (NASDAQ: KALA), 혁신적인 안질환 치료제를 개발하는 임상 단계의 생물 의약품 회사가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참가한다고 발표했습니다. 발표는 2025년 3월 5일 오전 11시 50분 ET에 매사추세츠주 보스턴에서 예정되어 있습니다.
회사의 경영진이 발표를 진행하며, 하루 종일 1:1 미팅을 위해 대기합니다. 관심 있는 분들은 www.kalarx.com의 '발표' 섹션을 통해 웹캐스트 및 이후 녹화에 접근할 수 있습니다.
KALA BIO (NASDAQ: KALA), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies innovantes pour les maladies oculaires, a annoncé sa participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. La présentation est prévue pour le 5 mars 2025 à 11h50 ET à Boston, MA.
L'équipe de direction de l'entreprise fera la présentation et sera disponible pour des réunions individuelles tout au long de la journée. Les parties intéressées peuvent accéder au webinaire et à l'enregistrement ultérieur via la section 'Présentations' sur www.kalarx.com.
KALA BIO (NASDAQ: KALA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Therapien für Augenerkrankungen konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Präsentation ist für 5. März 2025, um 11:50 Uhr ET in Boston, MA, angesetzt.
Das Managementteam des Unternehmens wird die Präsentation halten und steht den ganzen Tag für Einzelgespräche zur Verfügung. Interessierte Parteien können über den Abschnitt 'Präsentationen' auf www.kalarx.com auf das Webcast und die nachfolgende Aufzeichnung zugreifen.
- None.
- None.
ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When and where is KALA BIO presenting at the TD Cowen Healthcare Conference 2025?
How can investors access KALA BIO's TD Cowen conference presentation?
What type of meetings is KALA BIO offering at the TD Cowen conference?
What is KALA BIO's current business focus in the healthcare sector?
